The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.

A complex endocrine disorder with genetic roots, affecting women's health and fertility, requiring early intervention.

There's a long way to go when it comes to sex and gender equity in medicine, but engineers at The University of New Mexico hope to close the gap with ...

Tennis legend Chris Evert, a two-time ovarian cancer survivor, is advocating for awareness and genetic screening after her ...

An interdisciplinary study uncovers how benign borderline ovarian tumors develop into invasive low-grade serous carcinoma, ...

Models of ovarian carcinogenesis have separated epithelial tumors into major pathways with distinct cells of origin, carcinogenic pathways, and histology with different clinical behavior. 8, 10 An ...

The following article specifically delves into ovary removal surgery as it relates to cisgender women.  Some people might assume that, when you have your uterus removed via hysterectomy, the surgeon ...

Most ovarian cancers start in the fallopian tubes. Research and prevention efforts aim to replace tube tying with tube removal, salpingectomy.

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer—and offers a potential pathway for new treatments.

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.

Study of epithelial cells from benign ovarian cystic teratomas showed the chromosome number and morphology of such cells to be within normal limits and to be female.